Vivos Therapeutics (VVOS) FCF Margin (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly FCF Margin of 117.06% for Q1 2026, up 1298.0% year-over-year from 8.37% in Q1 2025, and up 44.99% quarter-over-quarter from 212.81% in Q4 2025.
Vivos Therapeutics (VVOS) FCF Margin (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported FCF Margin for 7 consecutive years, with 117.06% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 1298.0% year-over-year to 117.06%; the TTM figure through Mar 2026 stood at 115.21% (down 1593.0% YoY), while the FY2025 annual figure was 117.23%, down 2896.0% from the prior year.
- FCF Margin climbed to 117.06% in Q1 2026 per VVOS's latest filing, from 212.81% in the prior quarter.
- Across five years, FCF Margin topped out at 60.7% in Q3 2025 and bottomed at 212.81% in Q4 2025.
- Historically, FCF Margin has averaged 109.87% across 5 years, with a median of 106.37% in 2023.
- Annual changes were most pronounced in 2023 — FCF Margin surged 7715 bps — and 2025, when it slumped 12861 bps.
- Vivos Therapeutics' FCF Margin stood at 81.34% in 2022, then slumped by 31 bps to 106.37% in 2023, then increased by 21 bps to 84.21% in 2024, then slumped by 153 bps to 212.81% in 2025, then surged by 45 bps to 117.06% in 2026.
- Business Quant data shows VVOS's FCF Margin at 117.06% in Q1 2026, 212.81% in Q4 2025, and 60.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.61 Bn | 194.01 Bn | 7.27 Bn | 15.81% |
| 2 | Stryker | 127.81 Bn | 124.34 Bn | 4.50 Bn | 16.07% |
| 3 | Medtronic | 119.04 Bn | 109.82 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 73.68 Bn | 73.14 Bn | 3.85 Bn | 23.50% |
| 5 | Edwards Lifesciences | 51.96 Bn | 47.71 Bn | 1.35 Bn | 33.60% |
| 6 | Dexcom | 34.36 Bn | 32.41 Bn | 830.00 Mn | 14.10% |
| 7 | GE HealthCare Technologies | 33.83 Bn | 31.72 Bn | 2.18 Bn | 1.28% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 5.32% |
| 9 | Steris | 23.06 Bn | 22.58 Bn | 684.20 Mn | 18.73% |
| 10 | Vivos Therapeutics | 4.97 Mn | 3.17 Mn | 2.95 Mn | -69.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.06% |
| Dec 31, 2025 | -212.81% |
| Sep 30, 2025 | -60.70% |
| Jun 30, 2025 | -111.81% |
| Mar 31, 2025 | -130.04% |
| Dec 31, 2024 | -84.21% |
| Sep 30, 2024 | -112.51% |
| Jun 30, 2024 | -77.55% |
| Mar 31, 2024 | -78.01% |
| Dec 31, 2023 | -106.37% |
| Sep 30, 2023 | -71.68% |
| Jun 30, 2023 | -97.00% |
| Mar 31, 2023 | -93.05% |
| Dec 31, 2022 | -81.34% |
| Sep 30, 2022 | -139.94% |
| Jun 30, 2022 | -123.49% |
| Mar 31, 2022 | -170.20% |
| Dec 31, 2021 | -102.50% |
| Sep 30, 2021 | -97.98% |
| Jun 30, 2021 | -112.30% |